ERBB2 and triple-negative breast carcinoma: These drugs could serve as a targeted therapy for 40% of women formerly diagnosed with early triple negative breast cancer, now re-categorised as HER2-low, representing approximately 48 women per year in NZ based on 2020 and 2021 data.